| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Amy Sullivan last filed a Form 4 in April 2025, as Chief Financial Officer at IOBT. Amy Sullivan's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 84,632 shares of IOBT. Net of sales, the IOBT filings show accumulation of 35,250 shares.
Amy Sullivan has 7 Form 4 filings on record from October 2022 to April 2025, all as Chief Financial Officer at IO Biotech (IOBT), 2022–2025.
The 8 reported transactions were 5 option or other derivative awards, 2 open-market purchases and 1 stock award.
Counted by filing, the open-market trades come to 2 purchases worth about $67K and no sales.
The largest open-market purchase was 25,000 shares of IOBT at an average $2.32 on March 17, 2023, about $58K. Twelve months later IOBT was down 17%.
Shares as reported in the last Form 4 for each company; the most recent is from April 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.